PolymarketComprobar disponibilidadSin KYC2% de comisiónProbabilidad implícita actualSí 12%-0.0%
Calidad del mercado
52 / 100
Calidad mediaVolumen 24h
238,8 €
Liquidez
2,4 mil €
Liquidez mediaCompra / Venta
11.0% / 12.0%
Spread
9.1%
Spread amplioCambio 7d
-4.5%
Datos de mercado
Actualizado hace 5 minutos
12 ene 26, 23:0931 dic 26, 0:00
Tendencias
Resultado elegido
Yes12%
También disponible en Kalshi
Will the FDA approve retatrutide?
11.0%6m
-11.0%17%
-7.0%85%
-7.0%87%
+2 resultados más
28 • Baja calidadSpread amplioBaja liquidezMercado poco profundo
Volumen total102 €
Volumen 24h5,1 €
KALSHIReglas
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
Las probabilidades pueden diferir debido a diferentes estructuras de mercado, comisiones y grupos de participantes.
Mercados Relacionados
Hantavirus pandemic in 2026?
145,3 mil €Sí: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16,6 mil €Sí: 10%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
8,7 mil €Sí: 8%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1,3 mil €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETSActivos en estos temas
Noticias Relacionadas
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsReglas
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs